Gt Biopharma Stock Market Value
| GTBP Stock | USD 3.52 0.05 1.40% |
| Symbol | GTBP |
GT Biopharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.01) | Return On Assets (0.54) | Return On Equity (1.05) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
GT Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to GT Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of GT Biopharma.
| 05/06/2024 |
| 06/05/2024 |
If you would invest 0.00 in GT Biopharma on May 6, 2024 and sell it all today you would earn a total of 0.00 from holding GT Biopharma or generate 0.0% return on investment in GT Biopharma over 30 days. GT Biopharma is related to or competes with Nutriband, and SAB Biotherapeutics. GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immu... More
GT Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure GT Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess GT Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.6 | |||
| Information Ratio | 0.0397 | |||
| Maximum Drawdown | 178.21 | |||
| Value At Risk | (10.67) | |||
| Potential Upside | 10.71 |
GT Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for GT Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as GT Biopharma's standard deviation. In reality, there are many statistical measures that can use GT Biopharma historical prices to predict the future GT Biopharma's volatility.| Risk Adjusted Performance | 0.0351 | |||
| Jensen Alpha | 0.8063 | |||
| Total Risk Alpha | 0.498 | |||
| Sortino Ratio | 0.1038 | |||
| Treynor Ratio | (0.99) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GT Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GT Biopharma Backtested Returns
GT Biopharma appears to be abnormally volatile, given 3 months investment horizon. GT Biopharma retains Efficiency (Sharpe Ratio) of 0.0417, which attests that the entity had a 0.0417% return per unit of price deviation over the last 3 months. By inspecting GT Biopharma's technical indicators, you can evaluate if the expected return of 0.85% is justified by implied risk. Please utilize GT Biopharma's Market Risk Adjusted Performance of (0.98), semi deviation of 7.01, and Standard Deviation of 19.87 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, GT Biopharma holds a performance score of 3. The company owns a Beta (Systematic Risk) of -0.8, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning GT Biopharma are expected to decrease at a much lower rate. During the bear market, GT Biopharma is likely to outperform the market. Please check GT Biopharma's coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether GT Biopharma's current price history will revert.
Auto-correlation | 0.05 |
Virtually no predictability
GT Biopharma has virtually no predictability. Overlapping area represents the amount of predictability between GT Biopharma time series from 6th of May 2024 to 21st of May 2024 and 21st of May 2024 to 5th of June 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of GT Biopharma price movement. The serial correlation of 0.05 indicates that only as little as 5.0% of current GT Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.05 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.47 |
GT Biopharma lagged returns against current returns
Autocorrelation, which is GT Biopharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting GT Biopharma's stock expected returns. We can calculate the autocorrelation of GT Biopharma returns to help us make a trade decision. For example, suppose you find that GT Biopharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
GT Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If GT Biopharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if GT Biopharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in GT Biopharma stock over time.
Current vs Lagged Prices |
| Timeline |
GT Biopharma Lagged Returns
When evaluating GT Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of GT Biopharma stock have on its future price. GT Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, GT Biopharma autocorrelation shows the relationship between GT Biopharma stock current value and its past values and can show if there is a momentum factor associated with investing in GT Biopharma.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.